Acadia

Acadia is advancing breakthroughs in neuroscience and rare disease to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most.

We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.